Rallybio Corp
RLYB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$16.65
KIRA · Stoqly’s AI analyst, in plain words
- Rallybio Corp had $0.9M of revenue in fiscal 2025, up 34.9% on the year before.
- Its operating margin was −3,853.6%, up 5,658.3 pts: of every 100 in sales, about −3,854 is left after running the business.
- Rallybio Corp lost $9.0M in fiscal 2025.
Market cap
$96.5M
P/E
2.6x
Revenue
$0.9M
Net income
−$9.0M
Free cash flow
—
Operating margin
−3,853.6%
Rallybio Corp in 30 seconds · fiscal 2025
Are sales growing?
+34.9%
Yes. Sales grew 34.9% last year.
Does it make a profit?
−1,046.4%
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
2.6x
One share costs 2.6 times its yearly profit per share.
What Rallybio Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Rallybio Corp
- CIK
- 0001739410
Rallybio Corp · RLYB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.6M | $0.9M |
| Revenue growth | — | — | — | — | 34.9% |
| Operating margin | — | — | — | −9,511.9% | −3,853.6% |
| Net income | −$47.0M | −$66.7M | −$74.6M | −$57.8M | −$9.0M |
| Net margin | — | — | — | −9,084.1% | −1,046.4% |
| Diluted EPS | −$1.84 | −$2.09 | −$1.84 | −$10.61 | −$1.59 |
| Cash | |||||
| Cash from operations | −$45.5M | −$57.3M | −$60.3M | −$49.3M | −$29.8M |
| Capital expenditure | $0.3M | $0.1M | $0.0M | $0.0M | — |
| Free cash flow | −$45.9M | −$57.3M | −$60.3M | −$49.3M | — |
| FCF margin | — | — | — | −7,748.7% | — |
| Share count change | 46.8% | 24.7% | 27.1% | −86.5% | 3.4% |
| Debt and strength | |||||
| Cash and short-term investments | $175M | $169M | $110M | $65.5M | $54.7M |
| Shareholders' equity | $176M | $169M | $106M | $61.7M | $58.0M |
| Current ratio | 27.6x | 16.7x | 12.4x | 10.9x | 14.5x |
| Interest coverage | −4,564.8x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −30.2% | −38.6% | −54.1% | −68.8% | −15.0% |
| Return on tangible equity | −26.8% | −39.4% | −70.2% | −93.7% | −15.5% |
| Piotroski F-score | — | — | — | — | 3 |
| Altman Z'' | 30.9 | 16.7 | 6.6 | −4.0 | 0.8 |
Insiders bought, 12 months
$4.2M
2 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rallybio Corp · RLYB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $16.65 a share, the company is worth $96.5M: 2.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001739410). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.